Dr. Konduri is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3410 Worth St
Dallas, TX 75246Phone+1 214-370-1000Fax+1 214-370-1202- Is this information wrong?
Education & Training
Baylor University Medical CenterFellowship, Hematology and Medical Oncology, 2001 - 2003
Rush University Medical CenterResidency, Internal Medicine, 1995 - 1998
Delhi University College of Medical SciencesClass of 1994
Certifications & Licensure
TX State Medical License 2002 - 2025
IL State Medical License 1995 - 2008
OK State Medical License 1998 - 2002- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC Start of enrollment: 2008 Jan 08
- Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Start of enrollment: 2011 Jan 11
- A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09
Publications & Presentations
PubMed
- Biomarker Testing for Actionable Alterations in NSCLC-Perspectives from US-Based Academic and Community Oncologists: A Podcast.Wade T Iams, Kartik Konduri> ;Advances in Therapy. 2023 Dec 1
- 1 citationsLocally Advanced Inflammatory Myofibroblastic Tumor Treated With Targeted Therapy: A Case Report and Literature Review.Charis Durham, Matthew Clemons, Alwin Alias, Kartik Konduri> ;Cureus. 2022 Jul 1
- 22 citationsRandomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)David R. Spigel, Robert M. Jotte, John Nemunaitis, Merrill Kingman Shum, Jeffrey A. Schneider, Jerome H. Goldschmidt, Jennifer L. Eisenstein, David Berz, Lasika Senevi...> ;Journal of Thoracic Oncology. 2021 Feb 1
- Join now to see all
Press Mentions
OncLive® Presents State of the Science Summit™ on Non-Small Cell Lung CancerApril 16th, 2019
Low Dose CT Scan May Save LivesNovember 20th, 2018
Clinical Trials Highlight Biomarker Progress in Lung CancerFebruary 21st, 2018
Professional Memberships
- Member
Hospital Affiliations
Baylor University Medical CenterDallas, Texas
Medical City DallasDallas, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
